[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"impaired-consciousness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:impaired-consciousness":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100611429","phase-2-bovis-calculus-stativus-treat-acute-cerebral-ischemic-stroke-with-impaired-consciousness-100611429",false,"NCT07240467","Bovis Calculus Stativus Treat Acute Cerebral Ischemic Stroke With Impaired Consciousness","Safety and Efficacy of Bovis Calculus Stativus in the Treatment of Acute Cerebral Ischemic Stroke With Impaired Consciousness- A Multicenter, Prospective, Double-blind, Randomized Trial","ASCENT-BC","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Clinically diagnosed with ischemic cerebral infarction;\n* GCS score: 3-12;\n* Time from symptom onset to randomization ≤ 24 hours, including wake-up stroke or stroke without a witness; the time of symptom onset is defined as the \"last known well time\";\n* Pre-stroke mRS score of 0-1;\n* Head CT excludes intracranial hemorrhage or other non-ischemic pathologies;\n* The participant or legally authorized representative is capable of providing informed consent.\n\nExclusion Criteria:\n\n* Use of in BCS within 24 hours before treatment;\n* Known pregnancy or breastfeeding, or positive pregnancy test before randomization;\n* Allergy to BCS;\n* Impaired consciousness caused by other diseases, such as metabolic disorders (e.g., ketoacidosis), trauma, infectious diseases (e.g., pneumonia), neoplastic diseases (e.g., glioma), or toxic conditions (e.g., organophosphate poisoning);\n* Requiring or undergoing hemodialysis or peritoneal dialysis; known severe renal insufficiency (glomerular filtration rate \\\u003C30 mL\u002Fmin or serum creatinine \\>220 μmol\u002FL);\n* Expected survival time less than 6 months (e.g., due to malignancy, severe cardiopulmonary disease, etc.);\n* Participation in other interventional clinical studies that may affect outcome assessment;\n* Other conditions deemed by the investigator to make the patient unsuitable for participation or pose significant risks (e.g., inability to understand and\u002For comply with study procedures and\u002For follow-up due to mental illness, cognitive or emotional disorders).","ALL","18 Years",{"count":20,"type":21},220,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Acute ischemic stroke (AIS) is a severe and life-threatening condition, with 35% of AIS patients experiencing impaired consciousness upon admission within 24 hours of onset. Previous studies indicated that patients with impaired consciousness at the onset of stroke have a higher incidence of stroke-related complications, particularly cerebral edema and pneumonia, as well as higher in-hospital and three-month mortality rates. The etiology of impaired consciousness in AIS is complex: ischemic damage to reticular activating system of the brainstem can directly lead to cell necrosis and result in impaired consciousness. Furthermore, secondary pathological changes following AIS, such as excitatory amino acid toxicity, oxidative stress, free radical production, and cascading inflammatory responses, can indirectly worsen impaired consciousness. Therefore, impaired consciousness at the onset of AIS is the result of cellular damage under multiple pathophysiological mechanisms. Developing neuroprotective drugs with multiple targets is key to effectively improving adverse outcomes related to impaired consciousness in AIS. However, there is currently a lack of treatment specifically aimed at improving impaired consciousness at the onset of AIS.\n\nCultivated Bovine Bezoar (Bovis Calculus Stativus, BCS) combines the advantages of pharmacological similarity to natural bovine by adding components such as deoxycholic acid, cholic acid, and composite calcium bilirubin to fresh bovine bile. It is rich in various trace elements and amino acids and is a compound medication that can exert neuroprotective effects through multiple pathways and targets. In traditional Chinese medicine, it has long been used to treat various consciousness disorder-related diseases, including stroke. The various components of in vitro cultivated bezoar are also widely used in clinical research for various neurological diseases.The above evidence fully demonstrates that BCS is an optimal treatment for impaired consciousness in stroke.\n\nThe goal of this clinical trial is to learn if Bovis Calculus Stativus works to treat acute cerebral ischemic stroke with impaired consciousness. It will also learn about the safety of Bovis Calculus Stativus. The main questions it aims to answer are:\n\n1. Does Bovis Calculus Stativus treat and alleviate consciousness disorders in patients with acute cerebral infarction accompanied by impaired consciousness ？\n2. What medical problems do participants have when taking Bovis Calculus Stativus?\n\nResearchers will compare Bovis Calculus Stativus to a placebo (a look-alike substance that contains no drug) to see if Bovis Calculus Stativus works to treat acute cerebral ischemic stroke with impaired consciousness.\n\nParticipants will:\n\n1. receive treatment with Bovis Calculus Stativus (or placebo) for 5 days.\n2. Take an in-person or telephone follow-up within 90 days after the acute stroke.",[28,29],"Acute Ischemic Stroke AIS","Impaired Consciousness",[31,32,33],"acute ischemic stroke","impaired consciousness","Bovis Calculus Stativus","NOT_YET_RECRUITING","2025-12-10",{"date":37,"type":38},"2025-12-18","ACTUAL",{"date":40,"type":21},"2025-12-15",{"date":42,"type":21},"2028-12-15",{"name":44,"class":45},"Xiang Luo","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":5},"100589740","neuroimmunology-registry-and-biobank-100589740","NCT06958341","Neuroimmunology Registry and Biobank","Registry for Patients With Antibody-mediated Neuroimmunological Diseases","Inclusion Criteria:\n\n1. Differential diagnosis: suspected neuroimmunological disease in which a lumbar puncture is indicated for further diagnosis and treatment decision\n2. Individuals with unclear clinical diagnosis where additional CSF is to be collected for isolation of B cells and production of monoclonal antibodies. The clinical condition of the patients and his\u002Fher compliance have to allow an extra 2-3 ml of CSF to be collected.\n3. Age: all age groups\n4. Gender: patients of both sexes will be included\n\nExclusion criteria:\n\n\\[1\\] Withdrawal of consent",{"count":54,"type":21},300,"OBSERVATIONAL","A variety of antineuronal antibodies have been detected in the cerebrospinal fluid (CSF) of patients with neurological diseases. This raises the question of whether these antibodies are disease-specific or merely an epiphenomenon of inflammatory processes in the brain.\n\nThe registry was established with the following objectives: \\[1\\] Are antineuronal antibodies much more common than previously thought in various neurological disorders for which the etiology has not yet been elucidated? \\[2\\] Can further correlations, such as those between HSV infection and NMDA receptor autoimmunity, be identified? \\[3\\] Are these antibodies mainly non-specific epiphenomena or are they crucial for the pathogenesis? \\[4\\] What is the clinical course of patients with antineuronal antibodies and their response to therapy? These questions will be addressed in a broad immunohistological screening of a large number of CSF samples and a clinical database of patients with neurological disorders.",[58,59,29,60,61,62,63,64],"Encephalopathy","Psychosis","Epilepsy","Movement Disorders","Motor Neuropathy","Spasticity","Ataxia",[66,67,68,69],"neuroimmunological diseases","cerebrospinal fluid","cell-based assay","tissue-based assay","RECRUITING","2025-05-03",{"date":73,"type":38},"2025-05-06",{"date":75,"type":38},"2021-02-01",{"date":77,"type":21},"2031-07-01",{"name":79,"class":45},"Charite University, Berlin, Germany"]